CodeMap®  150 North Wacker Drive
Suite 1870
Chicago, IL 60606
847-381-5465 Phone
847-381-4606 Fax
customerservice@codemap.com
      


2020 Printed Publications Early Bird Sale on Now through August 30, 2019!



User Information

Create New Account

Lost Password

Username:
Password:


Quick Links

PLA Codes

Laboratory Fee Schedule

2019
2018

Physician Fee Schedule

2019
2018

OPPS Fee Schedule

2019-July
2019-April

ASC Fee Schedule

2019-July
2019-April

APC Codes

2019-July
2019-April

DRG Codes

2019
2018

ASP Drug Pricing Files

July 2019
April 2019


CMS Transmittals



National Coverage Determination
Procedure Code: 8XXXX
Human Immunodeficiency Virus (HIV) Testing (Prognosis Including Monitoring)
CMS Policy Number: 190.13
Back to NCD List

Description: HIV quantification is achieved through the use of a number of different assays which measure the amount of circulating viral RNA. Assays vary both in methods used to detect viral RNA as well as in ability to detect viral levels at lower limits. However, all employ some type of nucleic acid amplification technique to enhance sensitivity, and results are expressed as the HIV copy number.

Quantification assays of HIV plasma RNA are used prognostically to assess relative risk for disease progression and predict time to death, as well as to assess efficacy of anti-retroviral therapies over time.

HIV quantification is often performed together with CD4+T cell counts which provide information on extent of HIV induced immune system damage already incurred.

Indications:
1. A plasma HIV RNA baseline level may be medically necessary in any patient with confirmed HIV infection.

2. Regular periodic measurement of plasma HIV RNA levels may be medically necessary to determine risk for disease progression in an HIV-infected individual and to determine when to initiate anti-retroviral treatment regimens.

3. In clinical situations where risk of HIV infection is significant and initiation of therapy is anticipated, a baseline HIV quantification may be performed. These situations include:
a. Persistence of borderline or equivocal serologic reactivity in an at-risk individual.
b. Signs and symptoms of acute retroviral syndrome characterized by fever, malaise, lymphadenopathy and rash in an at-risk individual.

Limitations:
1. Viral quantification may be appropriate for prognostic use including baseline determination, periodic monitoring, and monitoring of response to therapy. Use as a diagnostic test method is not indicated.

2. Measurement of plasma HIV RNA levels should be performed at the time of establishment of an HIV infection diagnosis. For an accurate baseline, 2 specimens in a 2-week period are appropriate.

3. For prognosis including anti-retroviral therapy monitoring, regular, periodic measurements are appropriate. The frequency of viral load testing should be consistent with the most current Centers for Disease Control and Prevention guidelines for use of anti-retroviral agents in adults and adolescents or pediatrics.

4. Because differences in absolute HIV copy number are known to occur using different assays, plasma HIV RNA levels should be measured by the same analytical method. A change in assay method may necessitate re-establishment of a baseline.

5. Nucleic acid quantification techniques are representative of rapidly emerging & evolving new technologies. Users advised to remain current on FDA-approval status.

Other:
Assessment of CD4+ T cell numbers is frequently performed in conjunction with viral load determination. When used in concert, the accuracy with which the risk for disease progression and death can be predicted is enhanced.

Frequency Limitations: Measurement of plasma HIV RNA levels should be performed at the time of establishment of an HIV infection diagnosis. For an accurate baseline, 2 specimens in a 2-week period are appropriate.



To review all requirements of this policy, please see: CMS NCD listing by Chapter

Covered ICD-10 Codes.

ICD-10Descriptor
B20 Human immunodeficiency virus [HIV] disease
B97.35 HIV 2 as the cause of diseases classified elsewhere
O98.411 Viral hepatitis complicating pregnancy, first trimester
O98.412 Viral hepatitis complicating pregnancy, second trimester
O98.413 Viral hepatitis complicating pregnancy, third trimester
O98.419 Viral hepatitis complicating pregnancy, unsp trimester
O98.42 Viral hepatitis complicating childbirth
O98.43 Viral hepatitis complicating the puerperium
O98.511 Other viral diseases complicating pregnancy, first trimester
O98.512 Oth viral diseases complicating pregnancy, second trimester
O98.513 Other viral diseases complicating pregnancy, third trimester
O98.519 Other viral diseases complicating pregnancy, unsp trimester
O98.52 Other viral diseases complicating childbirth
O98.53 Other viral diseases complicating the puerperium
O98.711 Human immunodef virus disease comp preg, first trimester
O98.712 Human immunodef virus disease comp preg, second trimester
O98.713 Human immunodef virus disease comp preg, third trimester
O98.719 Human immunodef virus disease comp pregnancy, unsp trimester
O98.72 Human immunodeficiency virus disease complicating childbirth
O98.73 Human immunodef virus disease complicating the puerperium
R75 Inconclusive laboratory evidence of human immunodef virus
Z21 Asymptomatic human immunodeficiency virus infection status

The content and format of the following files and/or webpages are copywritten and the property of Wheaton Partners, LLC - dba CodeMap®. All recipients of these files agree not to distribute, reproduce and/or use the information contained within, in any manner not expressly agreed upon by the user and Wheaton Partners, LLC - dba CodeMap®.

All code-pairs and Medicare coverage information are compiled directly from Center for Medicare and Medicaid Services (CMS) and Medicare Contractor coverage policies. CodeMap® has made every reasonable effort to ensure the accuracy of the information contained. However, the ultimate responsibility for correct coding and claims submission lies with the provider of services. Both CMS and Medicare contractor coverage policy information may change at any time. CodeMap® makes no representation, warranty, or guarantee that this compilation of coverage policy information is error-free or that the use of this information will result in Medicare coverage and subsequent payment of claims. Final coverage and payment of claims are subject to many factors exclusively controlled by CMS and its contractors.


CodeMap® is a Registered Trademark of Wheaton Partners, LLC.